🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,254 results for “First” Clear

  1. Tislelizumab + SOX Chemotherapy

    First Tracks Biotherapeutics

    Gastric Cancer Stage III

    phase 3 small molecule active

    1 trial

  2. Tovorafenib, VINCRISIN 1 mg/ml solution injectable, 2 mg, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tovorafenib, VELBE 10 mg Trockensubstanz zur Injektionsbereitung, Vinblastin STADA 10 mg Pulver zur Herstellung einer Injektionslösung, cellcristin® 1 mg/ml Injektionslösung Wirkstoff: Vincristinsulfat, Vincristinesulfaat Teva 1 mg/ml, oplossing voor injectie, Vinblastinesulfaat 1 mg/ml PCH, oplossing voor injectie

    Pharma Mar S.A.

    Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy

    phase 3 small molecule active

    1 trial

  3. Tranexamic acid

    First Tracks Biotherapeutics

    Hemorrhage, Postpartum

    phase 3 small molecule completed

    1 trial

  4. Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of ≥6 hours between doses) for three months.

    First Tracks Biotherapeutics

    Post-stroke Epilepsy

    phase 3 small molecule active

    1 trial

  5. Triptorelin for Injection

    First Tracks Biotherapeutics

    Ovarian Hyperstimulation Syndrome

    phase 3 small molecule active

    1 trial

  6. Trophic enteral feeding combined with supplemental parenteral nutrition

    First Tracks Biotherapeutics

    Severe Stroke

    phase 3 other active

    1 trial

  7. Two Anti-angiogenesis Drugs（Endostar and Thalidomide）

    First Tracks Biotherapeutics

    Colorectal Neoplasms

    phase 3 small molecule active

    1 trial

  8. Tyrosine kinase inhibitor (TKIs)

    First Tracks Biotherapeutics

    Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  9. UDCA

    First Tracks Biotherapeutics

    Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  10. Ustekinumab

    First Tracks Biotherapeutics

    Crohn Disease

    phase 3 small molecule active

    1 trial

  11. Venetoclax

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  12. Venetoclax in combination with fludarabine and melphalan

    First Tracks Biotherapeutics

    Venentoclax

    phase 3 small molecule active

    1 trial

  13. Venetoclax, AZACITIDINE, Venetoclax, azacitidine, Venetoclax, azacitidine

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia in First Remission

    phase 3 small molecule active

    1 trial

  14. Visilizumab

    First Tracks Biotherapeutics

    Immunotherapy

    phase 3 small molecule active

    1 trial

  15. Ypeginterferon alfa-2b

    First Tracks Biotherapeutics

    Chronic Hepatitis B

    phase 3 small molecule completed

    3 trials

  16. decitabine

    First Tracks Biotherapeutics

    Acute Myelocytic Leukemia

    phase 3 small molecule active

    1 trial

  17. decitabine

    First Tracks Biotherapeutics

    Poor Graft Function

    phase 3 small molecule active

    1 trial

  18. didroxyprogesterone

    First Tracks Biotherapeutics

    Pregnancy Rate

    phase 3 small molecule active

    1 trial

  19. different degrees of adjustment of the injection interval

    First Tracks Biotherapeutics

    Exudative Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  20. donor lymphocyte infusion

    First Tracks Biotherapeutics

    Minimal Residual Disease

    phase 3 mab completed

    1 trial

  21. esophagectomy

    First Tracks Biotherapeutics

    Esophageal Cancer

    phase 3 other active

    1 trial

  22. metformin

    First Tracks Biotherapeutics

    Polycystic Ovary Syndrome

    phase 3 small molecule completed

    1 trial

  23. mitoxantrone liposome, Ara-Cytarabine and azacitidine

    First Tracks Biotherapeutics

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  24. mycophenolate mofetil 2 g per day

    First Tracks Biotherapeutics

    Lymphocytic Myocarditis (Disorder)

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources